Li Yiwei, Weng Qianping, Huang Xilian, Xie Yaping, Chen Can, Qian Shenxian
Department of Hematology, Affiliated Hangzhou First People's Hospital, Nanjing Medical University.
Department of Hematology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, PR. China.
Medicine (Baltimore). 2020 Sep 4;99(36):e22033. doi: 10.1097/MD.0000000000022033.
In December 2019, the novel coronavirus pneumonia was detected in Wuhan and named COVID-19. It is an international outbreak of the respiratory illness caused by severe acute respiratory syndrome coronavirus 2. Recent papers pointed out the cytopenia in COVID-19 patients including lymphopenia, neutrophilia, thrombocytopenia and lower level of hemoglobin had prognostic significance. This systemic review and meta-analysis summaries the latest evidence from available data and determine the hematological abnormality caused by severe acute respiratory syndrome coronavirus 2 and potential efficacy on the outcomes in patients with COVID-19.
This protocol for a systematic reviews and meta-analysis will be performed according to the preferred reporting items for systematic reviews and meta-analysis protocols 2015 guidelines. The database of Cochrane Library, PUBMED, EMBASE, Medline, Web of Science, Google Scholar, CNKI, WanFang, as well as gray literatures from the inception to present will be comprehensively and systematically searched without limitations of regions or language. The main study outcomes will be the mortality of COVID-19 patients. The meta-analysis was performed by RevMan V.5.3 program and Stata V.12.0 software after 2 reviewers independently selected literature, data extraction, bias risk evaluation and study quality assessment. Any disagreement will be resolved by consensus to the third researcher.
This systematic review and meta-analysis may help provide clarify on the effect of cytopenia in patients with COVID-19. The result will be published at a peer-reviewed journal.
This proposed study will evaluate the existing evidence on the effectiveness of cytopenia in COVID-19 patients.
The content of this article does not involve moral approval or ethical review because no individual data will be collected.
CRD42020187524.
2019年12月，在武汉检测到新型冠状病毒肺炎，并命名为COVID-19。它是由严重急性呼吸综合征冠状病毒2引起的一种国际呼吸道疾病暴发。近期论文指出，COVID-19患者的血细胞减少，包括淋巴细胞减少、中性粒细胞增多、血小板减少和血红蛋白水平降低，具有预后意义。本系统评价和荟萃分析总结了现有数据的最新证据，确定了严重急性呼吸综合征冠状病毒2引起的血液学异常及其对COVID-19患者预后的潜在影响。
本系统评价和荟萃分析方案将根据2015年系统评价和荟萃分析方案首选报告项目指南进行。将全面、系统地检索Cochrane图书馆、PUBMED、EMBASE、Medline、Web of Science、谷歌学术、中国知网、万方数据库以及自创建以来的灰色文献，不受地区或语言限制。主要研究结局将是COVID-19患者的死亡率。在2名评审员独立进行文献筛选、数据提取、偏倚风险评估和研究质量评估后，使用RevMan V.5.3程序和Stata V.12.0软件进行荟萃分析。如有任何分歧，将通过与第三位研究人员达成共识来解决。
本系统评价和荟萃分析可能有助于阐明COVID-19患者血细胞减少的影响。结果将在同行评审期刊上发表。
本拟议研究将评估现有证据，以证明COVID-19患者血细胞减少的有效性。
本文内容不涉及道德批准或伦理审查，因为不会收集个人数据。
PROSPERO注册：CRD42020187524。
